VIDEO: No improvement with addition of irinotecan to FOLFOX panitumumab for patients with metastatic colorectal cancer
Click Here to Manage Email Alerts
In this video, Smitha S. Krishnamurthi, MD, discussed the results of the TRIPLETE trial, which she said showed no improvement when irinotecan was added to FOLFOX panitumumab in patients with mostly unresectable RAS and BRAF wild-type left-sided metastatic colorectal cancer.
The phase 3 randomized study, presented at ASCO Annual Meeting, evaluated the overall response rate of first-line modified FOLFOXFIRI plus panitumumab vs. FOLFOX plus panitumumab.
The researchers had hypothesized that FOLFOX plus panitumumab would show a 60% response rate and with the addition of irinotecan that would be improved by 15%.
“In this trial most of the patients had a left-sided primary tumor because, of course, we've learned that EGFR antibodies do not benefit patients in the first-line setting when the primary tumor is on the right side," Krishnamurthi. a gastrointestinal medical oncologist at the Cleveland Clinic, said.
"What we're finding is that this population of patients with RAS and BRAF wild-type metastatic colorectal cancer with a left-sided primary tumor have much better outcomes with chemotherapy, much higher response rates, so the surprise finding of the TRIPLETE trial was that adding irinotecan to FOLFOX panitumumab did not improve the response rate," Krishnamurthi said, noting that the response rate was quite high. With FOLFOX plus panitumumab, response rate was 76% and 73% with FOLFOXFIRI plus panitumumab.
Collapse
Read more about
Click Here to Manage Email Alerts